Major histocompatibility complex class II–peptide complex (MHC II–peptide complex) (MHC II–peptide complex)

Major histocompatibility complex class II (MHC II)–peptide complexes are essential cell-surface structures that mediate the recognition of foreign antigens by the adaptive immune system. These complexes are primarily expressed on professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells (UniProt, 2024). They consist of a heterodimeric protein (alpha and beta chains) that binds and displays peptide fragments derived from extracellular proteins to CD4+ T helper cells. This interaction is a cornerstone of immune surveillance, enabling the activation of B cells for antibody production and the coordination of inflammatory responses (NCBI Bookshelf, 2023). In the context of disease, specific MHC II alleles are the strongest genetic risk factors for autoimmune conditions like rheumatoid arthritis and type 1 diabetes, where they present self-peptides that trigger an attack on host tissues (PubMed, 2022). Therapeutic approaches targeting these complexes include antigen-specific immunotherapies and monoclonal antibodies designed to modulate or inhibit the T-cell response to specific pMHCII targets (Frontiers in Immunology, 2021).

Other names

HLA class II–peptide complexpMHCIIMHC II–antigen complexHuman leukocyte antigen class II–peptide complexMHC class II–antigenic peptide complex

MHC II–peptide complexes function by presenting processed exogenous antigens to the T-cell receptor (TCR) of CD4+ T cells. This interaction, stabilized by the CD4 co-receptor, triggers a signaling cascade that leads to T-cell proliferation and cytokine secretion (Janeway's Immunobiology, 2001). Drugs targeting this complex either compete for the peptide-binding groove, block the TCR-MHC II interface, or utilize the complex to deliver tolerogenic signals to prevent autoimmunity (Nature Reviews Immunology, 2017).